Krassimir Ivandjiiski
Home Archive Search Sponsors About us Contact

Translate
Select Language




Russia To Being Using Its First Approved COVID-19 Drug, Avifavir


Russia To Being Using Its First Approved COVID-19 Drug, Avifavir

By

Carol Duff, MSN, BA, RN-

1 June

 

Russia to roll out its first approved COVID-19 drug next week

 

 

by Andrew Osborn/Reuters

MOSCOW (Reuters) – Russia will start giving its first drug approved to treat COVID-19 to patients next week, its state financial backer told Reuters, a move it hopes will ease strains on the health system and speed a return to normal economic life.

Russian hospitals can begin giving the antiviral drug, which is registered under the name Avifavir, to patients from June 11, the head of Russia’s RDIF sovereign wealth fund told Reuters in an interview. He said the company behind the drug would manufacture enough to treat around 60,000 people a month.

There is currently no vaccine for COVID-19, the disease caused by the new coronavirus, and human trials of several existing antiviral drugs have yet to show efficacy.

A new antiviral drug from Gilead (GILD.O) called remdesivir has shown some promise in small efficacy trials against COVID-19 and is being given to patients by some countries under compassionate or emergency use rules.

Avifavir, known generically as favipiravir, was first developed in the late 1990s by a Japanese company later bought by Fujifilm as it moved into healthcare.

RDIF head Kirill Dmitriev said Russian scientists had modified the drug to enhance it, and said Moscow would be ready to share….read more:

Exclusive: Russia to roll out its first approved COVID-19 drug next week

 

Andrew Osborn 

 

MOSCOW (Reuters) - Russia will start giving its first drug approved to treat COVID-19 to patients next week, its state financial backer told Reuters, a move it hopes will ease strains on the health system and speed a return to normal economic life.

 

 

FILE PHOTO: Paramedics and members of the Emergencies Ministry wearing personal protective equipment (PPE) push a stretcher into an ambulance while transporting a patient amid the coronavirus disease (COVID-19) outbreak in the city of Tver, Russia May 28, 2020. REUTERS/Tatyana Makeyeva/File Photo

Russian hospitals can begin giving the antiviral drug, which is registered under the name Avifavir, to patients from June 11, the head of Russia’s RDIF sovereign wealth fund told Reuters in an interview. He said the company behind the drug would manufacture enough to treat around 60,000 people a month.

There is currently no vaccine for COVID-19, the disease caused by the new coronavirus, and human trials of several existing antiviral drugs have yet to show efficacy.

 

A new antiviral drug from Gilead (GILD.O) called remdesivir has shown some promise in small efficacy trials against COVID-19 and is being given to patients by some countries under compassionate or emergency use rules.

Avifavir, known generically as favipiravir, was first developed in the late 1990s by a Japanese company later bought by Fujifilm as it moved into healthcare.

RDIF head Kirill Dmitriev said Russian scientists had modified the drug to enhance it, and said Moscow would be ready to share the details of those modifications within two weeks.

 

Japan has been trialling the same drug, known there as Avigan. It has won plaudits from Prime Minister Shinzo Abe and $128 million in government funding, but has yet to be approved for use.

Avifavir appeared on a Russian government list of approved drugs on Saturday.

ACCELERATED PROCESS

Dmitriev said clinical trials of the drug had been conducted involving 330 people, and had shown that it successfully treated the virus in most cases within four days.

 

The trials were due to be concluded in around a week, he said, but the health ministry had given its approval for the drug’s use under a special accelerated process and manufacturing had begun in March.

Clinical trials to test efficacy drugs usually take many months, even when expedited, and involve large numbers of patients randomly assigned who receive either the drug being trialled or a control or placebo.

Success in small small-scale, early-stage trials is no guarantee of success in later, more comprehensive trials.

A study published this month, for example, tied the anti-malarial drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking and has urged others to use, to an increased risk of death in hospitalised COVID-19 patients. 

 

 


 



 

 
"Строго секретно" излиза от 1991г. Вестникът е уникално издание за кулисите на висшата политика, геополитиката, шпионажа, финансовите престъпления, конспирацията, невероятното, трагичното и смешното.
Strogo Sekretno is the home for the highest politics, geopolitics, geo-economics, world crisis, weapons, intelligence, financial crimes...
(c) 1991-2020, Strogosekretno.com, All Rights Reserved
Contents may not be reproduces in whole or in part without permission of publisher. Information presented in Strogo Sekretno may or may not represent the views of Strogo Sekretno, its staff, or its advertisers.
Strogo Sekretno assume no responsibility for the reliability of advertisements presented in the newspaper. Strogo Sekretno respects the privacy of our subscribers. Our subscriber mailing list is not available for sale or sharing.
Reprint permission: contact@strogosekretno.com